Impact of Digoxin on Mortality in Patients with Atrial Fibrillation Stratified by Heart Failure: Findings from Gulf Survey of Atrial Fibrillation Events in the Middle East

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2016, Pages 273-279

  Al Zakwani, Ibrahim ^a,b   Panduranga, P ^c   Zubaid, M ^d   Sulaiman, K ^c   Rashed, W A ^e   Alsheikh Ali, A A ^f,g   Almahmeed, W ^h   Shehab, A ⁱ   Al Qudaimi, A ^j   Asaad, N ^k   Amin, H ^l  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b Gulf Health Research   (Oman)

^c ROYAL HOSPITAL   (Oman)

^d KUWAIT UNIVERSITY   (Kuwait)

^e MUBARAK AL KABEER HOSPITAL   (Kuwait)

^f SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^g Dubai Healthcare City   (United Arab Emirates)

^h HEART AND VASCULAR INSTITUTE   (United Arab Emirates)

ⁱ UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^j Al Thawra Hospital   (Yemen)

^k HAMAD MEDICAL CORPORATION   (Qatar)

^l Mohammed Bin Khalifa Cardiac Centre   (Bahrain)

more..

Author keywords

atrial fibrillation; digoxin; heart failure; middle east; mortality

Indexed keywords

DIGOXIN; ANTIARRHYTHMIC AGENT; CARDIOTONIC AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDDLE EAST; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; AGED; CLINICAL TRIAL; EPIDEMIOLOGY; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SELECTION; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; PATIENT SELECTION; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84963665525     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415603505     Document Type: Article

References (24)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J. 2010; 31 (19): 2369-2429.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130 (23): e272-e274.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62 (16): e147-e239.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14 (8): 803-869.
5. See I, Shehab N, Kegler SR, Laskar SR, Budnitz DS,. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circ Heart Fail. 2014; 7 (1): 28-34.
6. Hallberg P, Lindbäck J, Lindahl B, et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007; 63 (10): 959-971.
7. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J. 2013; 34 (20): 1481-1488.
8. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L,. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol. 2014; 114 (3): 401-406.
9. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014; 64 (7): 660-668.
10. Freeman JV, Yang J, Sung SH, et al. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013; 6 (5): 525-533.
11. Chao TF, Liu CJ, Chen SJ, et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol. 2014; 30 (10): 1190-1195.
12. Friberg L, Hammar N, Rosenqvist M,. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart. 2010; 96 (4): 275-280.
13. Rodríguez-Mañero M, Otero-Raviña F, García-Seara J, et al. Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. Rev Esp Cardiol. 2014; 67 (11): 890-897. doi:10.1016/j.recesp.2014.01.015.
14. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013; 34 (20): 1489-1497.
15. Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014; 11 (9): 1543-1550.
16. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes. 2011; 4 (4): 477-482.
17. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Management and 1 year morbidity and mortality outcomes of patients with atrial fibrillation in the Middle East: The Gulf Survey of Atrial Fibrillation Events (Gulf SAFE). Angiology. 2015; 66 (5): 464-471.
18. McNamara RL, Brass LM, Drozda JP Jr, et al. American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation); American College of Cardiology; American Heart Association. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation. 2004; 109 (25): 3223-3243.
19. Gjesdal K, Feyzi J, Olsson S,. Digitalis-a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008; 94 (2): 191-196.
20. Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015; 385 (9985): 2363-2370. pii: S0140-6736(14)61836-5. doi:10.1016/S0140-6736(14)61836-5.
21. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336 (8): 525-533.
22. Pastori D, Farcomeni A, Bucci T, et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2015; 180: 1-5.
23. Chirinos J, Castrellon A, Zambrano J, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005; 2 (5): 525-529.
24. Chan K, Lazarus J, Hakim R,. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010; 21 (9): 1550-1559.